Stachydrine effectively inhibits several receptor tyrosine kinases, including BCR-ABL, which is crucial in the treatment of chronic myeloid leukemia (CML). Here, NTRK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.